Is Kymera Therapeutics Inc (KYMR) overvalued? · rev $99.4M
Kymera Therapeutics Inc (KYMR) is a biotechnology company listed on NASDAQ.
This page asks whether Kymera Therapeutics Inc (KYMR) looks expensive on cached numbers — not a short thesis.
Latest reported KYMR revenue for 2026-06-30 was $99.4M. Net income was -$130.4M. KYMR currently screens at market cap $7.39B.
KYMR currently screens at market cap $7.39B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next KYMR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the KYMR stock page for the full model, not this heading.
Not investment advice.